Laura K Seppälä1, Laura-Maria Madanat-Harjuoja1,2, Rebecca Troisi3, Joshua N Sampson4, Maarit K Leinonen5, Kim Vettenranta1. 1. Pediatrics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 2. Finnish Cancer Registry, Helsinki, Finland. 3. Division of Cancer Epidemiology and Genetics, Transdivisional Research Program, National Cancer Institute, Rockville, United States. 4. Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, United States. 5. Unit of Data and Analytics, Information Services Department, Finnish Institute of Health and Welfare, Helsinki, Finland.
Abstract
AIM: Autoimmune disease and its medication are associated with increased cancer risk in adults, but it is unknown whether maternal autoimmune disease and/or medication use in pregnancy are associated with increased cancer risk in offspring. METHODS: In this case-control study, we identified all patients under 20 years of age with their first cancer diagnosis in 1996-2014 from the Finnish Cancer Registry (n = 2029) and 1:5 population-based controls (n = 10,103) from the Medical Birth Register. We obtained information on maternal autoimmune disease and its medication from the relevant Finnish registries and used conditional logistic regression to analyse the risk of offspring cancer after maternal autoimmune disease exposure. RESULTS: The odds ratio (OR) for cancer in offspring following maternal autoimmune exposure was 0.76 (95% confidence interval [CI] 0.47-1.23). Individual ORs for inflammatory bowel and connective tissue diseases were 1.08 (95% CI 0.56-2.01) and 0.50 (95% CI 0.23-1.08), respectively. The OR for maternal autoimmune medication was 0.95 (95% CI 0.80-1.14) overall and similar by drug subtype. There was an increased risk with medication in late pregnancy but the ORs were unstable owing to small numbers. CONCLUSION: Our study does not support an increased cancer risk among offspring of women with autoimmune disease or its medication during pregnancy.
AIM: Autoimmune disease and its medication are associated with increased cancer risk in adults, but it is unknown whether maternal autoimmune disease and/or medication use in pregnancy are associated with increased cancer risk in offspring. METHODS: In this case-control study, we identified all patients under 20 years of age with their first cancer diagnosis in 1996-2014 from the Finnish Cancer Registry (n = 2029) and 1:5 population-based controls (n = 10,103) from the Medical Birth Register. We obtained information on maternal autoimmune disease and its medication from the relevant Finnish registries and used conditional logistic regression to analyse the risk of offspring cancer after maternal autoimmune disease exposure. RESULTS: The odds ratio (OR) for cancer in offspring following maternal autoimmune exposure was 0.76 (95% confidence interval [CI] 0.47-1.23). Individual ORs for inflammatory bowel and connective tissue diseases were 1.08 (95% CI 0.56-2.01) and 0.50 (95% CI 0.23-1.08), respectively. The OR for maternal autoimmune medication was 0.95 (95% CI 0.80-1.14) overall and similar by drug subtype. There was an increased risk with medication in late pregnancy but the ORs were unstable owing to small numbers. CONCLUSION: Our study does not support an increased cancer risk among offspring of women with autoimmune disease or its medication during pregnancy.
Authors: Heather Zierhut; Martha S Linet; Leslie L Robison; Richard K Severson; Logan Spector Journal: Cancer Epidemiol Date: 2011-10-21 Impact factor: 2.984
Authors: Karin Ekström; Henrik Hjalgrim; Lena Brandt; Eva Baecklund; Lars Klareskog; Anders Ekbom; Johan Askling Journal: Arthritis Rheum Date: 2003-04
Authors: Lene Mellemkjaer; Ruth M Pfeiffer; Eric A Engels; Gloria Gridley; William Wheeler; Kari Hemminki; Jørgen H Olsen; Lene Dreyer; Martha S Linet; Lynn R Goldin; Ola Landgren Journal: Arthritis Rheum Date: 2008-03